Q-omics provides the consensus-scored LPGAT1-AS1 profile across patient tissues and cancer cell-line models. LPGAT1-AS1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, LPGAT1-AS1 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, LPGAT1-AS1 RNA expression shows 6,806 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, LIHC, and STAD as cancer lineages where LPGAT1-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LPGAT1-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LPGAT1-AS1 survival associations across molecular data types. LPGAT1-AS1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LPGAT1-AS1 RNA expression–survival associations across cancer types. High LPGAT1-AS1 expression shows unfavorable associations in THYM, DLBC, LIHC and KIRC, but favorable associations in BRCA and MESO. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for LPGAT1-AS1 RNA expression.
This table summarizes LPGAT1-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LPGAT1-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LPGAT1-AS1 shows lower tumor expression in THCA and higher tumor expression in LIHC, KIRP, BRCA and LUAD. The LIHC box plot shows higher LPGAT1-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p < 0.001).
This table shows molecular features associated with LPGAT1-AS1 in patient tissues and cancer cell lines. In patient samples, LPGAT1-AS1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
